^
Association details:
Biomarker:No biomarker
Cancer:Hepatocellular Cancer
Drug:Opdivo (nivolumab) (PD1 inhibitor) +
Yervoy (ipilimumab) (CTLA4 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of... patients with hepatocellular carcinoma who have been previously treated with sorafenib, as a single agent or in combination with ipilimumab.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Combined nivolumab and ipilimumab are recommended for patients with Child-Pugh A.